To our knowledge, there are a limited number of studies examining the relationship between CDH17 immunohistochemical expression and a comprehensive range of clinicopathological features [23,24], as well as survival outcomes [24] in CRC. This evidence concerns the gene CDH17 and colorectal carcinoma.